Navigation Links
Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders
Date:5/19/2009

DOYLESTOWN, Pa., May 19 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that it has uncovered additional facts with respect to the relationship between Ted Karkus and Dr. Richard Rosenbloom. The following are among the facts that were uncovered:

  1. Karkus admitted in a press release today that he loaned $55,000 to Dr. Rosenbloom. Karkus is, and has been, a shareholder of The Quigley Corporation and Dr. Rosenbloom is, and has been, in possession of material non-public information as to the Company's drug candidate development programs during the term of the loan.
  2. In sworn testimony, Karkus stated that at no time did he have any financial arrangement with any employee of The Quigley Corporation. By his own admission in today's press release, this is a false statement which he made under oath.
  3. Karkus has been in touch with Company officials. The fact has never been disclosed in the proxy materials or otherwise.
  4. In clear violation of Company policy, Dr. Rosenbloom has never disclosed his relationship with dissident Karkus.
  5. According to Dr. Rosenbloom in an interview conducted by executives of the Company prior to The Quigley Corporation's press release earlier today, Dr. Rosenbloom advised that he had been offered an increase in salary and an undisclosed amount of stock to continue with the Karkus Group if the Karkus Group were victorious in gaining control of the Company.
  6. The proposed arrangement between Karkus and Dr. Rosenbloom has never been disclosed in any of Karkus's proxy solicitation material in violation of federal securities laws.

The Company assures its shareholder
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
2. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
3. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
4. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
5. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
6. US FDA Admits Risks of Mercury Dental Fillings, Settles Lawsuit
7. Sutter Admits: Closing St. Lukes Likely to Reduce Charity Care
8. International Isotopes Inc. Announces First Quarter 2009 Financial Results
9. Apieron Strengthens Senior Leadership With Commercial, Financial Appointments
10. BMP Sunstone Reports First Quarter 2009 Financial Results
11. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... Dartmouth has been awarded one of 30 grants from ... Lead Academic Participating Site in its new National ... a select groups of investigators charged with distributing resources ... The NCTN grant system reflects recommendations from a ... to achieve four goals:, Faster design, launch, ...
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... clinical trials for a new experimental drug to ... Patients treated with CPX-351, a combination of the ... responses than patients treated with the standard drug ... is an aggressive blood cancer with very low ... explained Jeffrey Lancet, M.D., senior member of the ...
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... how low doses of arsenic, such as the levels found ... affect human physiology. In a paper published online on Dec. ... report that three different steroid hormones all show similar responses ... of arsenic on how these hormones function. ,"Since ...
... by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park ... chronic lymphocytic leukemia (CLL) or diseases that no longer ... the therapy. The results of this study were published ... Clinical Oncology. ,"Chronic lymphocytic leukemia is ...
... arithmetic or to make change for a dollar. She is ... can’t write down her name clearly, nor can she cross ... person. She can sing like a nightingale although her IQ ... she knows hundreds of songs in Italian, German French, Macedonian, ...
... U.S firm Schwarz has found to be potential in reducing ... drugs - the company said on Monday following the results ... the 485-patient study were presented at the North American Regional ... 200-mg dose of the drug, lacosamide, had 14.4 percent fewer ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... of obesity, as a causative factor for breast cancer. It ... factor for cancer, heart disease, stroke and diabetes. Scientists have ... breast cancer. ,Latest research has indicated that having ... female hormones, the presence of which elevates the risk of ...
Cached Medicine News:Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 2Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 3Health News:Heavenly Notes from a Life Etched With Disability: The Strangest Song 2Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Cardinal Health today announced the launch of its new ... increase efficiencies and minimize waste in acute drainage, biopsy ... trays include the essential clinical supplies needed for each ... organizing supplies for procedures and the amount of waste ...
... Pharmaceuticals International, Inc. (NYSE: VRX ... acquired Probiotica Laboratorios Ltda., a leader in sports ... markets a full line of over-the-counter sports nutrition ... percent share of the market. Valeant will acquire ...
Cached Medicine Technology:Cardinal Health Introduces Diagnostic Procedure Trays 2Valeant Pharmaceuticals Acquires Probiotica in Brazil 2
... gel electrophoresis system mirrors a 96-well plate ... of PCR products to take place easily ... (96-well) plate. Loading can be carried out directly ... time in the industry two sets of ...
... Platform is designed with a spring-loaded mechanism ... E-Gel® 48 gel cassettes stay firmly in ... placement and loading from one gel to ... to the robot loading software. In addition, ...
... seamless eliminating the possibility of leakage around glued ... temperature resistant gel trays meaning you do no ... added user friendliness, the Primo tanks come with ... The Primo Gel Systems are designed to be ...
Designed for rapid, routine electrophoresis for nucleic acids. The Mini unit is designed with a choice of two casting systems: standard casting trays that require sealing tape; or aluminum-gated cast...
Medicine Products: